DRI Healthcare Trust

What DRI Healthcare Trust does

DRI Healthcare Trust (formerly DRI Capital, founded 1989) is a Toronto-domiciled, publicly traded investment trust on the TSX (DHT.UN) that specializes in pharmaceutical royalty monetization. The company acquires dependable, patent-protected cash-flow streams derived from the sales of approved and developing drugs, having deployed more than US$3.0 billion since inception across 77 royalties on 50-plus products spanning oncology, neurology, ophthalmology, immunology, hematology, dermatology, lysosomal storage disorders, and rare diseases. Its current portfolio comprises 28 royalty streams on 22 products with an intangible royalty asset book value of US$752.9 million as of March 31, 2026.

DRI generates revenue primarily through two transaction structures: traditional royalty purchases (buying existing royalty streams from inventors, academic institutions, and biotechs at a lump sum) and synthetic royalties (contracting directly with the product marketer for a percentage of net sales in exchange for upfront and milestone financing). Notable assets include Eylea (Regeneron/Bayer), Keytruda, Stelara (J&J), Spinraza (Biogen), Zejula (GSK), Casgevy (Vertex), and recent additions Sebetralstat/Ekterly (KalVista) and Veligrotug/VRDN-003 (Viridian Therapeutics, up to US$300M total potential investment). Q1 2026 Total Income was a record US$50.6M with Adjusted EBITDA of US$52.8M (90% margin).

The company serves two counterparties: biopharmaceutical innovators (biotech companies, academic institutions, and individual inventors) seeking non-dilutive capital, and unit-holders on the TSX seeking differentiated exposure to pharmaceutical sales. Distribution is exclusively through direct, relationship-based transactions; deal flow is sourced via 35 years of industry relationships rather than traditional marketing. Capital is accessed via public equity, a US$500M syndicated credit facility (TD, CIBC, HSBC, BofA, JPMorgan), and recent 2026 issuances of US$250M senior secured notes and C$108.7M convertible debentures. DRI internalized its investment management function from DRI Capital Inc. in Q2 2025, transitioning from an externally managed structure to self-management.

Name

DRI Healthcare Trust

Legal name

DRI Healthcare Trust

Website

https://drihealthcare.com

Company type

Public

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

DRI Healthcare Trust is a Toronto-listed pharmaceutical royalty monetization trust that provides non-dilutive capital to biotechs, academics, and inventors in exchange for royalty interests on approved and developing drugs, serving biopharmaceutical innovators and TSX unit-holders.

Ownership category

akta.pro rank

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Infrastructure, Others

Revenue model

1. Royalty Income: DRI Healthcare generates revenue by acquiring royalty streams from pharmaceutical products. Royalties are typically a percentage of net sales of commercialized drugs, providing recurring income from patent-protected cash flow streams. The company has acquired royalties on over 50 drugs across multiple therapeutic areas.
2. Synthetic Royalty Financing: DRI Healthcare provides upfront capital to biotech companies in exchange for synthetic royalty interests on product sales. This non-dilutive financing for biotech companies includes upfront payments and potential milestone payments tied to clinical and regulatory achievements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

DRI Healthcare Trust acquires dependable, patent-protected cash flow streams derived from the sales of important pharmaceutical products. The company provides capital to biopharmaceutical innovators—including individual inventors, academic institutions, and biotech companies—in exchange for royalty interests. It operates through traditional royalty purchases (buying existing royalty streams) and synthetic royalty financing (contracting directly with marketers for new royalty streams tied to product sales).

Product overview

DRI Healthcare Trust operates as a pioneer in global pharmaceutical royalty monetization, providing capital to biopharmaceutical innovators in exchange for royalty interests in approved and developing drugs. The company does not offer a traditional software product; rather, its core offering is acquiring and managing a diversified portfolio of royalty streams on pharmaceutical products across multiple therapeutic areas including oncology, neurology, ophthalmology, immunology, and rare diseases. The portfolio includes both traditional royalties (acquiring existing royalty streams from innovators) and synthetic royalties (creating new royalty streams by contracting directly with marketers). Key royalty assets include Eylea, Keytruda, Stelara, Orserdu, Omidria, Spinraza, Vonjo, Zejula, Zytiga, Xolair, Casgevy, and Veligrotug/VRDN-003. The company serves investors seeking exposure to pharmaceutical sales without direct drug development risk, and innovators seeking non-dilutive capital.

Differentiator

Problem solved

Functional benefit

Products and services

• Traditional Royalty Acquisitions Traditional royalty purchases where DRI pays an initial purchase price to biopharmaceutical innovators in return for some or all of the royalties under the license agreement, typically a percentage of net sales of the commercialized drug.
• Synthetic Royalty Financing Synthetic royalty transactions where DRI Healthcare contracts directly with the product marketer to receive a portion of top-line product sales in exchange for upfront funding, creating a new royalty stream. Includes potential milestone payments tied to clinical and regulatory achievements.
• Eylea Royalty Interest Royalty interest in Eylea, an ophthalmology drug marketed by Regeneron, Bayer, and Santen. One of the key assets in DRI Healthcare's current portfolio.
• Keytruda Royalty Interest Royalty interest in Keytruda, an immunotherapy drug. Part of DRI Healthcare's diversified portfolio of therapeutic assets.
• Stelara Royalty Interest Royalty interest in Stelara, an immunology drug marketed by Johnson & Johnson. Part of DRI Healthcare's diversified portfolio.
• Orserdu Royalty Interest Royalty interest in Orserdu, an oncology drug marketed by Menarini. Included in DRI Healthcare's current portfolio.
• Omidria Royalty Interest Royalty interest in Omidria, an ophthalmology drug marketed by Rayner Surgical. Significant revenue contributor in DRI Healthcare's portfolio.
• Spinraza Royalty Interest Royalty interest in Spinraza, a neurology drug marketed by Biogen. Part of DRI Healthcare's diverse therapeutic portfolio.
• Veligrotug Synthetic Royalty Interest Synthetic royalty interest in U.S. sales of Veligrotug, a Thyroid Eye Disease (TED) treatment acquired from Viridian Therapeutics. Part of a transaction with total potential investment of up to US$300 million.

Quantifiable outcome

• Q1 2026 Total Income of $50.6 million, a record for the company
• +2 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Viridian TherapeuticscoreStrategic or Co-development Partner · 17 October 2025DRI Healthcare acquired a synthetic royalty interest in U.S. sales of veligrotug and VRDN-003 from Viridian Therapeutics for thyroid eye disease treatment. Total potential investment of up to $300 million including $55 million upfront payment and milestone payments up to $205 million. DRI Healthcare also has a put option and buyback provisions related to a potential change of control following KalVista/Chiesi acquisition announcement.
• DRI Capital Inc.coreOthers · 22 October 2022DRI Capital Inc. is the investment manager of DRI Healthcare Trust, providing investment management services. In 2025, DRI Healthcare completed the internalization of its investment management function.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Royalty Pharma: Royalty Pharma is the largest pure-play pharmaceutical royalty buyer and the public-market benchmark for the model. It acquires royalty interests in commercial and late-stage drugs, directly competing with DRI for both traditional and synthetic royalty transactions.
• Ligand Pharmaceuticals: Ligand operates a royalty-based business model generating revenue from licensed drug technologies across multiple therapeutic areas. Its royalty-driven income stream and diversified portfolio mirror DRI's structure, though Ligand focuses on technology licensing rather than asset purchases.
• XOMA Corporation: XOMA acquires royalty and milestone interests in late-stage clinical and commercial assets, funded by royalty monetization transactions. It shares DRI's specialty finance approach to biotech royalties with a more clinical-stage tilt.
• Healthcare Royalty Partners: Healthcare Royalty Partners (HCR), now part of KKR, is a direct competitor that purchases healthcare royalty streams and provides capital to life sciences companies. It competes with DRI for both traditional royalties and structured royalty financings.

Broad incumbents

• Bain Capital Life Sciences: Bain Capital Life Sciences provides growth and structured capital to biopharma, including royalty and non-dilutive financing arrangements. It is a broad incumbent with the scale to outbid DRI on premium transactions and offer competing synthetic royalty terms.
• OrbiMed Advisors: OrbiMed is a leading healthcare-dedicated investment firm spanning venture, growth, and royalty/credit strategies. Its royalty and structured capital activities compete with DRI in the biotech financing market, particularly for clinical and commercial-stage assets.
• Blackstone Life Sciences: Blackstone Life Sciences is a large-scale life sciences investment platform providing capital, royalty financing, and R&D partnerships to biopharma. It competes for high-value structured deals where DRI is also active, with substantially larger capital pools.
• KKR Health Care Strategic Growth: KKR's healthcare growth platform is a large, well-capitalized incumbent that includes the Healthcare Royalty Partners franchise. It competes broadly for healthcare royalty and structured financing deals and has deeper capital and origination capacity than DRI.

Emerging players

• Soleus Capital: Soleus Capital is a healthcare-focused investment firm that pursues public and private biotech opportunities including royalty and structured financing deals. It is a smaller, more specialized competitor that overlaps with DRI in royalty acquisitions.
• HealthCare Royalty Partners / Oaktree: Oaktree and similar credit-oriented platforms have expanded into healthcare royalty and structured finance. These emerging buyers compete with DRI for mid-sized royalty transactions and synthetic royalty arrangements with clinical-stage biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dri-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DRI Healthcare Trust